ZYUS Life Sciences (TSE:ZYUS) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ZYUS Life Sciences Corporation, a Canadian life sciences firm, has secured a CAD$1,000,000 unsecured loan from an independent director to bolster its working capital. The loan, with a 12% annual interest rate, is due by April 2025 but can be repaid earlier if the company raises at least $10 million through equity offerings. This financial move is expected to support ZYUS in its mission to develop non-opioid pain management therapies.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
